Atossa Therapeutics (ATOS) vs BeyondSpring (BYSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BeyondSpring (BYSI) has outperformed Atossa Therapeutics (ATOS) over the past year, losing 66.0% versus a loss of 85.5%. Over five years, ATOS leads with a -94.4% price change compared with -96.3% for BYSI. BeyondSpring is the larger company by market cap ($25.0 million vs $24.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATOS | BYSI |
|---|---|---|
| Share price | $2.42 | $0.609 |
| Market cap | $24.15M | $25.04M |
| 1-day change | -1.63% | -5.51% |
| YTD return | -72.66% | -62.64% |
| 1-year return | -85.47% | -65.98% |
| 5-year return | -94.36% | -96.32% |
| EPS (TTM) | $-4.45 | $-0.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.00 | $2.44 |
| 52-week low | $1.70 | $0.566 |
| Distance from 52-week high | -86.56% | -75.04% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +685.12% | — |
| Average volume | 63.48K | 855.31K |
| Shares outstanding | 9.98M | 41.12M |
| Employees | 16 | 44 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BYSI has outperformed ATOS by 19.5 percentage points over the past year.
About Atossa Therapeutics
ATOS stock →Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
Healthcare · Biotechnology · 16 employees
About BeyondSpring
BYSI stock →BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on developing and selling clinical-stage biopharmaceutical therapies focused on oncology and immunology. The company operates through two segments: the Plinabulin pipeline and the TPD platform.
Healthcare · Biotechnology · 44 employees
ATOS vs BYSI FAQ
Which is bigger, Atossa Therapeutics or BeyondSpring?
BeyondSpring (BYSI) is larger, with a market capitalization of $25.04M compared with $24.15M for Atossa Therapeutics (ATOS).
Which stock has performed better over the past year, ATOS or BYSI?
BYSI returned -65.98% over the past 12 months, compared with -85.47% for ATOS (price return, excluding dividends). Past performance does not predict future results.
Are Atossa Therapeutics and BeyondSpring in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.